HK1214816A1 - 作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法 - Google Patents

作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法

Info

Publication number
HK1214816A1
HK1214816A1 HK16102739.4A HK16102739A HK1214816A1 HK 1214816 A1 HK1214816 A1 HK 1214816A1 HK 16102739 A HK16102739 A HK 16102739A HK 1214816 A1 HK1214816 A1 HK 1214816A1
Authority
HK
Hong Kong
Prior art keywords
substituted
receptor
pyrazines
triazolo
dihydro
Prior art date
Application number
HK16102739.4A
Other languages
English (en)
Inventor
Hamid Hoveyda
Guillaume Dutheuil
Graeme Fraser
Original Assignee
Euroscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroscreen Sa filed Critical Euroscreen Sa
Publication of HK1214816A1 publication Critical patent/HK1214816A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16102739.4A 2013-03-29 2016-03-09 作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法 HK1214816A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13161863 2013-03-29
EP13193025 2013-11-15
EP14154303 2014-02-07
PCT/EP2014/056367 WO2014154895A1 (en) 2013-03-29 2014-03-28 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS

Publications (1)

Publication Number Publication Date
HK1214816A1 true HK1214816A1 (zh) 2016-08-05

Family

ID=50391185

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18103649.9A HK1244273A1 (zh) 2013-03-29 2016-03-09 作為選擇性nk-3受體拮抗劑的n-酰基-(3-取代)-(8-取代)-5，6-二氫-[1，2，4]***並[4，3-a]吡嗪、藥物組合物、用於nk-3受體介導的病症的方法
HK16102739.4A HK1214816A1 (zh) 2013-03-29 2016-03-09 作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18103649.9A HK1244273A1 (zh) 2013-03-29 2016-03-09 作為選擇性nk-3受體拮抗劑的n-酰基-(3-取代)-(8-取代)-5，6-二氫-[1，2，4]***並[4，3-a]吡嗪、藥物組合物、用於nk-3受體介導的病症的方法

Country Status (27)

Country Link
US (3) US9422299B2 (zh)
EP (2) EP3219715A1 (zh)
JP (2) JP6316932B2 (zh)
KR (2) KR102364835B1 (zh)
CN (1) CN105229008B (zh)
AU (1) AU2014242906B2 (zh)
BR (1) BR112015024907B1 (zh)
CA (1) CA2907809C (zh)
CY (1) CY1119576T1 (zh)
DK (1) DK2948455T5 (zh)
EA (1) EA027570B1 (zh)
ES (1) ES2646488T3 (zh)
HK (2) HK1244273A1 (zh)
HR (1) HRP20171688T1 (zh)
HU (1) HUE035870T2 (zh)
IL (1) IL241473B (zh)
LT (1) LT2948455T (zh)
MX (1) MX370000B (zh)
NO (1) NO2948455T3 (zh)
NZ (1) NZ712802A (zh)
PL (1) PL2948455T3 (zh)
PT (1) PT2948455T (zh)
RS (1) RS56501B1 (zh)
SG (1) SG11201508005XA (zh)
SI (1) SI2948455T1 (zh)
WO (1) WO2014154895A1 (zh)
ZA (1) ZA201506234B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011234398B8 (en) 2010-04-02 2015-03-05 Ogeda Sa Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
KR102049534B1 (ko) 2011-10-03 2019-11-27 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
EP2989103B1 (en) 2013-03-29 2019-02-20 Ogeda Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
CA2907809C (en) 2013-03-29 2021-05-04 Euroscreen Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
EP2978766B1 (en) 2013-03-29 2018-12-19 Ogeda Sa N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
SG10201800162RA (en) 2014-09-25 2018-02-27 Ogeda Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
EA036709B1 (ru) * 2015-03-16 2020-12-10 Огеда Са Применение антагонистов рецептора нейрокинина-3 для терапевтического или косметологического лечения излишних жировых отложений на теле
KR102122470B1 (ko) * 2016-12-08 2020-06-12 주식회사 엘지화학 변성제 및 이로부터 유래된 작용기를 포함하는 변성 공액디엔계 중합체
EP3428168A1 (en) 2017-07-12 2019-01-16 Ogeda Sa Deuterated fezolinetant
JP2021014404A (ja) * 2017-10-13 2021-02-12 アステラス製薬株式会社 トリアゾロピラジン誘導体の塩及び結晶
JP2020050814A (ja) * 2018-09-28 2020-04-02 住友ベークライト株式会社 フェノール変性リグニン樹脂を含む樹脂材料、それを用いたフェノール変性リグニン樹脂組成物および構造体
KR20210106528A (ko) 2018-12-21 2021-08-30 오게다 에스.에이. 3-메틸-1,2,4-티아디아졸-5-카보하이드라지드 또는 이의 메틸-d3 중수소화 형태의 합성
WO2020211798A1 (zh) * 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN113527307A (zh) * 2020-04-20 2021-10-22 上海翰森生物医药科技有限公司 含***基的并环类衍生物抑制剂、其制备方法和应用
CN113549074A (zh) * 2020-04-26 2021-10-26 上海翰森生物医药科技有限公司 含***基的并环类衍生物抑制剂、其制备方法和应用
US20230271969A1 (en) * 2020-07-30 2023-08-31 Shanghai Hansoh Biomedical Co., Ltd. Nitrogen-containing fused ring derivative inhibitor, preparation method therefor and use thereof
US20230271967A1 (en) 2020-08-04 2023-08-31 Teva Pharmaceuticals International Gmbh Solid state forms of fezolinetant and salts thereof
CN115260180B (zh) * 2021-04-30 2024-05-28 长春金赛药业有限责任公司 含三氮唑稠环类衍生物、药物组合物及其制备方法和应用
CN115990164A (zh) * 2021-10-18 2023-04-21 武汉大学 速激肽受体3抑制剂的用途
AU2023209540A1 (en) * 2022-01-24 2024-05-02 Changzhou Hansoh Pharmaceutical Co., Ltd. Acidic salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method therefor and use thereof
WO2024083150A1 (zh) * 2022-10-19 2024-04-25 长春金赛药业有限责任公司 一种nk3r拮抗剂的晶型及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2237408T3 (es) 1999-01-25 2005-08-01 Smithkline Beecham Corporation Antiandrogenos y procedimientos para tratar una enfermedad.
CA2478389A1 (en) 2002-03-25 2003-10-09 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
EP1628948A1 (de) 2003-05-21 2006-03-01 Bayer CropScience AG Difluormethylbenzanilide und deren verwendung zur bekämpfung von mikroorganismen, sowie zwischenprodukte und deren herstellung
CA2556320A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists for the treatment of gastrointestinal disorders
GB0509405D0 (en) 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
SE528833C2 (sv) 2005-07-29 2007-02-27 Metso Paper Inc System och metod för att behandla cellulosamassa i samband med utmatning från en satskokare
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2424869B1 (en) * 2009-04-29 2016-06-22 Glaxo Group Limited 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
AU2011234398B8 (en) 2010-04-02 2015-03-05 Ogeda Sa Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
KR102049534B1 (ko) 2011-10-03 2019-11-27 오게다 에스.에이. 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법
CA2907809C (en) * 2013-03-29 2021-05-04 Euroscreen Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
EP2989103B1 (en) 2013-03-29 2019-02-20 Ogeda Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
SG10201800162RA (en) 2014-09-25 2018-02-27 Ogeda Sa Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines

Also Published As

Publication number Publication date
RS56501B1 (sr) 2018-02-28
DK2948455T3 (da) 2017-11-20
BR112015024907A2 (pt) 2017-07-18
AU2014242906A2 (en) 2015-11-05
IL241473B (en) 2019-03-31
MX370000B (es) 2019-11-28
HK1244273A1 (zh) 2018-08-03
KR102218621B1 (ko) 2021-02-22
EP3219715A1 (en) 2017-09-20
US9422299B2 (en) 2016-08-23
KR102364835B1 (ko) 2022-02-17
MX2015013711A (es) 2016-02-26
JP2016515565A (ja) 2016-05-30
CA2907809C (en) 2021-05-04
WO2014154895A1 (en) 2014-10-02
PT2948455T (pt) 2017-11-15
KR20160007515A (ko) 2016-01-20
SG11201508005XA (en) 2015-10-29
DK2948455T5 (en) 2018-03-19
ES2646488T3 (es) 2017-12-14
SI2948455T1 (sl) 2017-12-29
CY1119576T1 (el) 2018-03-07
CN105229008B (zh) 2017-12-15
HRP20171688T1 (hr) 2017-12-29
ZA201506234B (en) 2019-01-30
PL2948455T3 (pl) 2018-01-31
US9987274B2 (en) 2018-06-05
IL241473A0 (en) 2015-11-30
BR112015024907B1 (pt) 2023-05-09
US20150232471A1 (en) 2015-08-20
JP6316932B2 (ja) 2018-04-25
KR20210021406A (ko) 2021-02-25
US10030025B2 (en) 2018-07-24
CN105229008A (zh) 2016-01-06
US20170095472A1 (en) 2017-04-06
CA2907809A1 (en) 2014-10-02
US20170240551A9 (en) 2017-08-24
US20160318941A1 (en) 2016-11-03
JP2018118988A (ja) 2018-08-02
NZ712802A (en) 2020-08-28
EA027570B1 (ru) 2017-08-31
EP2948455A1 (en) 2015-12-02
EP2948455B1 (en) 2017-09-27
EA201591689A1 (ru) 2016-01-29
HUE035870T2 (hu) 2018-05-28
LT2948455T (lt) 2017-11-27
AU2014242906B2 (en) 2018-07-26
NO2948455T3 (zh) 2018-02-24
AU2014242906A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
HK1214816A1 (zh) 作為選擇性 受體拮抗劑的新型 -酰基- -取代 -取代 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法
HK1218546A1 (zh) 作為選擇性 受體拮抗劑的新型 -醯基- -取代 -甲基 -二氫- ***並 吡嗪、藥物組合物、用於 受體介導的病症的方法
HK1217947A1 (zh) 新的 -酰基- -取代 -四氫- ***並 -α 吡嗪作為選擇性 受體拮抗劑、其藥物組合物、用於 受體介導的病症的方法
HK1197676A1 (zh) 作為選擇性 受體拮抗劑的新型手性 -酰基- -取代的 -四氫- ***並 吡嗪、藥物組合物、用於 受體介導的疾病中的方法
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
PL3838274T3 (pl) Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
SG11201509503QA (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
HK1182094A1 (zh) -二氫- -茚- -基- -二氮雜螺 壬烷衍生物及其作為生長激素釋放肽受體的拮抗劑或反向激動劑的用途
RS58129B1 (sr) Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za tretman respiratornih bolesti
IL251304A0 (en) New chiral synthesis of n-acyl-(3-disubstituted)-(8-disubstituted)-6,5-dihydro-[4,2,1]triazolo[4,3-a]pyrazines
EP2305678A4 (en) TETRAHYDRO-PYRAZOLOÝ1,5-A¨PYRIDO -PYRIMIDINES AS SERO-TONE 5-HT6 RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING SAME
EP2248815A4 (en) 3-SULFONYLPYRAZOLO [1,5-A] PYRIMIDINES / ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THEIR PREPARATION AND THEIR USE
EP2351756A4 (en) SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO [1,5-A] PYRIMIDINES, SEROTONIN-5-HT6 RECEPTOR ANTAGONISTS, AND METHOD FOR THEIR PREPARATION AND USE
AP3511A (en) NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]BENZO-DIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH HETEROCYCLIC DERIVATIVES